|
Schizophrenia
|
0.320 |
Biomarker
|
disease |
BEFREE |
Therefore, this study uncovers an important role for TLX and miR-219 in both normal neurodevelopment and in SCZ patient iPSC-derived NSCs.
|
26965827 |
2016 |
|
Schizophrenia
|
0.320 |
GeneticVariation
|
disease |
BEFREE |
Nuclear receptor 2E1 gene (NR2E1) resides within a 6q21-22 locus for bipolar disorder and schizophrenia.
|
18205168 |
2008 |
|
Schizophrenia
|
0.320 |
Biomarker
|
disease |
PSYGENET |
We also performed a comprehensive mutation screen of NR2E1, resequencing its entire coding region, complete 5' and 3' untranslated regions, consensus splice-sites, and evolutionarily conserved regions in 126 humans with bipolar disorder, schizophrenia, or aggressive disorders.
|
18205168 |
2008 |
|
Bipolar Disorder
|
0.310 |
Biomarker
|
disease |
PSYGENET |
The effect of lithium, a drug used to treat BP, was also evaluated for its ability to attenuate Nr2e1(frc/frc) behavioral and neural stem cell-proliferation phenotypes.
|
20497236 |
2010 |
|
Bipolar Disorder
|
0.310 |
Biomarker
|
disease |
BEFREE |
NR2E1 was associated with bipolar disorder I and II [odds ratio (OR = 0.77, P = 0.013), bipolar disorder I (OR = 0.77, P = 0.015), bipolar disorder in females (OR = 0.72, P = 0.009), and with age at onset < or = 25 years (OR = 0.67, P = 0.006)], all of which remained significant after correcting for multiple comparisons.
|
18205168 |
2008 |
|
Bipolar Disorder
|
0.310 |
Biomarker
|
disease |
PSYGENET |
NR2E1 was associated with bipolar disorder I and II [odds ratio (OR = 0.77, P = 0.013), bipolar disorder I (OR = 0.77, P = 0.015), bipolar disorder in females (OR = 0.72, P = 0.009), and with age at onset < or = 25 years (OR = 0.67, P = 0.006)], all of which remained significant after correcting for multiple comparisons.
|
18205168 |
2008 |
|
Bipolar I disorder
|
0.300 |
Biomarker
|
disease |
PSYGENET |
The NR2E1 region on Chromosome 6q21-22 has been repeatedly linked to bipolar disorder (BP) and NR2E1 has been associated with BP, and more specifically bipolar I disorder (BPI).
|
20497236 |
2010 |
|
Brain Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
Orphan nuclear receptor TLX (NR2E1) plays a critical role in the regulation of neural stem cells (NSC) as well as in the development of NSC-derived brain tumors.
|
30441799 |
2018 |
|
Brain Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
Here, we will highlight recent progress in the roles of TLX in brain development and adult neurogenesis, and the relevance of TLX to neurological diseases and brain tumors.
|
28527574 |
2017 |
|
Brain Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
TLX is a promising therapeutic target in neurological disorders and brain tumors.
|
26554934 |
2016 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
Moreover, we identify TET3 as a potent tumour suppressor downstream of TLX to regulate the growth and self-renewal in GSCs.
|
26838672 |
2016 |
|
Brain Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
The druggable orphan nuclear receptor TLX (NR2E1) is characterized as an important regulator of neural stem cells and is also implicated in the development of some brain tumours.
|
25557355 |
2015 |
|
Neoplasms
|
0.070 |
GeneticVariation
|
group |
BEFREE |
Furthermore, enhancement of TLX activity, by either ectopic expression or ligand stimulation, could potently prevent doxorubicin-induced senescence in prostate cancer cells and also allow prostatic epithelial cells to escape oncogene-induced senescence induced either by activated oncogene H-Ras(G12V) or knockdown of tumour suppressor PTEN, via a mechanism of direct but differential transcriptional regulation of two senescence-associated genes, repression of CDKN1A and transactivation of SIRT1.
|
25557355 |
2015 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
We demonstrate that the knock down of TLX in IMR-32 cells diminishes its tumor sphere-forming capacity.
|
25356871 |
2014 |
|
Neoplasms
|
0.070 |
GeneticVariation
|
group |
BEFREE |
These data revealed two subgroups of PA that separate according to tumor location (infratentorial versus supratentorial), and identified key neural developmental genes that are differentially methylated between the two groups, including NR2E1 and EN2.
|
23660940 |
2013 |
|
Brain Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
Taken together, these results indicate a critical role for TLX in NSC-dependent gliomagenesis and implicate TLX as a therapeutic target to inhibit the development of NSC-derived brain tumors.
|
23028043 |
2012 |
|
Neoplasms
|
0.070 |
AlteredExpression
|
group |
BEFREE |
Reverse engineering of TLX oncogenic transcriptional networks identifies RUNX1 as tumor suppressor in T-ALL.
|
22366949 |
2012 |
|
Brain Neoplasms
|
0.070 |
AlteredExpression
|
group |
BEFREE |
Here we demonstrate that the nuclear receptor tailless (Tlx), which in the adult is expressed exclusively in astrocyte-like B cells of the subventricular zone, acts as a key regulator of neural stem cell (NSC) expansion and brain tumor initiation from NSCs.
|
20360385 |
2010 |
|
Brain Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
Here, we report a tumorigenic role of TLX in brain tumor initiation and progression.
|
20814749 |
2010 |
|
Neoplasms
|
0.070 |
AlteredExpression
|
group |
BEFREE |
Ectopic expression of TLX in the U87MG glioma cell line and Ink4a/Arf-deficient mouse astrocytes (Ink4a/Arf(-/-) astrocytes) induced cell proliferation with a concomitant increase in cyclin D expression, and accelerated foci formation in soft agar and tumor formation in in vivo transplantation assays.
|
20814749 |
2010 |
|
Neoplasms
|
0.070 |
AlteredExpression
|
group |
BEFREE |
Overall, these results identify PHF6 as a new X-linked tumor suppressor in T-ALL and point to a strong genetic interaction between PHF6 loss and aberrant expression of TLX transcription factors in the pathogenesis of this disease.
|
20228800 |
2010 |
|
Malignant Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
Therefore, inhibitors of TLX transcriptional activity may have a significant impact on the treatment of several critical malignancies.
|
30441799 |
2018 |
|
Malignant Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
Pairwise analysis identified five orphan NRs (including RORβ, TLX, COUP-TFII, NURR1 and LRH-1) that showed common upregulation in both mRNA and protein levels in the prostatospheroids and castration-relapse VCaP-CRPC xenografts, and overexpression of these orphan NRs could increase cancer stem cell marker expressions and enhance spheroid formation capacity in prostate cancer cells, suggesting that these orphan NRs might perform positive roles in the growth regulation of PCSCs and castration-resistant prostate cancer.
|
29042395 |
2018 |
|
Carcinogenesis
|
0.040 |
AlteredExpression
|
phenotype |
BEFREE |
Our previous study shows that the orphan nuclear receptor TLX (NR2E1), which is upregulated in prostate cancer, plays an oncogenic role in prostate carcinogenesis by suppressing oncogene-induced senescence.
|
29555975 |
2018 |
|
Carcinogenesis
|
0.040 |
AlteredExpression
|
phenotype |
BEFREE |
Downregulation of TLX induces TET3 expression and inhibits glioblastoma stem cell self-renewal and tumorigenesis.
|
26838672 |
2016 |